The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    ELVN

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05650879
Recruitment Status : Recruiting
First Posted : December 14, 2022
Last Update Posted : May 23, 2024
Sponsor:
Information provided by (Responsible Party):
Enliven Therapeutics

Brief Summary:
The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-small cell lung cancer.

Condition or disease Intervention/treatment Phase
HER2 Mutant Non-small Cell Lung Cancer HER2-positive Metastatic Breast Cancer HER2 Gene Mutation HER2 Amplification Drug: ELVN-002 Drug: Fam-Trastuzumab Deruxtecan-Nxki Drug: Trastuzumab emtansine Phase 1

Detailed Description:

There are 4 parts to the trial. Part 1 is a dose escalation with ELVN-002 monotherapy for people with advanced stage solid tumors that have a HER2 mutation, amplification or high HER2 over-expression. Part 2 is an ELVN-002 monotherapy dose exploration where additional people may be enrolled at dose levels that have cleared the dose escalation in Part 1 to further evaluate the safety, tolerability, pharmacokinetics and clinical activity. Part 3 is a dose expansion of ELVN-002 monotherapy which will enroll up to 40 patients people with advanced stage HER2 mutant non-small cell lung cancer. Patients in Part 3 will be randomized 1:1 to receive one of two dose levels.

Part 4 is a combination dose escalation where, based on the results of Part 1 and 2, a combination of ELVN-002 and either fam-trastuzumab deruxtecan-nxki (in HER2 mutant non-small cell lung cancer) or trastuzumab emtansine (in HER2 positive breast cancer) will be evaluated for safety and tolerability.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 178 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Phase 1 will be a dose escalation monotherapy according to the Bayesian Optimal Interval Design model Phase 1b will be a dose expansion: up to 40 patients randomized between 2 dose levels
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
Actual Study Start Date : March 20, 2023
Estimated Primary Completion Date : July 2026
Estimated Study Completion Date : July 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Phase 1a Monotherapy Dose Escalation
ELVN-002 will be administered either once or twice daily. Each cohort of patients will receive a higher dose. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
Drug: ELVN-002
capsule

Experimental: Phase 1a Monotherapy Dose Exploration
ELVN-002 will be administered either once or twice daily. A maximum of 60 patients will enroll in this arm. A maximum of 10 patients may be enrolled at a single dose or tumor type. ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
Drug: ELVN-002
capsule

Experimental: Phase 1b Monotherapy Dose Expansion

ELVN-002 will be administered either once or twice daily. A maximum of 40 patients will enroll in this arm. Patients will be randomized 1:1 to one of two dose levels.

ELVN-002 is an oral capsule. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.

Drug: ELVN-002
capsule

Experimental: Phase 1a Combination Dose Escalation with T-DXd
ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 5.4mg/kg of intravenous T-DXd once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
Drug: ELVN-002
capsule

Drug: Fam-Trastuzumab Deruxtecan-Nxki
intravenous
Other Names:
  • Enhertu
  • T-DXd

Experimental: Phase 1a Combination Dose Escalation with T-DM1
ELVN-002 will be administered either once or twice daily starting on Day 1. ELVN-002 is an oral capsule. Each cohort will receive a higher dose of ELVN-002. All patients in all cohorts will initiate with 3.6 mg/kg of intravenous T-DM1 once every 3 weeks starting on day 22 of the study. Duration of treatment will be until disease progression or patient discontinues ELVN-002 for another reason.
Drug: ELVN-002
capsule

Drug: Trastuzumab emtansine
intravenous
Other Names:
  • Kadcyla
  • T-DM1




Primary Outcome Measures :
  1. Incidence of dose limiting toxicities in Phase 1a monotherapy [ Time Frame: 21 days ]
  2. Incidence of adverse events in Phase 1a monotherapy [ Time Frame: 24 months ]
  3. incidence of laboratory abnormalities in Phase 1a monotherapy [ Time Frame: 24 months ]
  4. incidence of ECG abnormalities in Phase 1a monotherapy [ Time Frame: 24 months ]
  5. incidence of dose limiting toxicities in Phase 1a combination with fam-trastuzumab deruxtecan (T-DXd) [ Time Frame: 42 days ]
  6. Incidence of adverse events in Phase 1a combination with T-DXd [ Time Frame: 24 months ]
  7. incidence of laboratory abnormalities in Phase 1a combination with T-DXd [ Time Frame: 24 months ]
  8. incidence of ECG abnormalities in Phase 1a combination with T-DXd [ Time Frame: 24 months ]
  9. incidence of dose limiting toxicities in Phase 1a combination with trastuzumab emantasine (T-DM1) [ Time Frame: 42 days ]
  10. Incidence of adverse events in Phase 1a combination with T-DM1 [ Time Frame: 24 months ]
  11. incidence of laboratory abnormalities in Phase 1a combination with T-DM1 [ Time Frame: 24 months ]
  12. incidence of ECG abnormalities in Phase 1a combination with T-DM1 [ Time Frame: 24 months ]
  13. Incidence of adverse events in Phase 1b monotherapy [ Time Frame: 24 months ]
  14. incidence of laboratory abnormalities in Phase 1b monotherapy [ Time Frame: 24 months ]
  15. incidence of ECG abnormalities in Phase 1b monotherapy [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Objective Response rate in Phase 1a monotherapy [ Time Frame: 24 months ]
    For patients with measurable disease at baseline, confirmed response per RECIST 1.1

  2. Objective response rate in Phase 1b monotherapy [ Time Frame: 24 months ]
    Confirmed response per RECIST 1.1

  3. Duration of response in Phase 1b monotherapy [ Time Frame: 24 months ]
    The time from the first response to progression or death per RECIST 1.1

  4. Brain metastases response in Phase 1b monotherapy [ Time Frame: 24 months ]
    for patients with measurable brain metastases at baseline, the percent of patients who have a confirmed response per RECIST 1.1

  5. PK parameter of area under the curve of ELVN-002 in Phase 1a monotherapy [ Time Frame: 21 days ]
    the concentration of ELVN-002 measured in the blood over 24 hours at steady state

  6. PK parameter of maximum concentration of ELVN-002 in Phase 1a monotherapy [ Time Frame: 21 days ]
    the maximum concentration of ELVN-002 measured in the blood at any time point at steady state

  7. PK parameter of terminal half life of ELVN-002 in Phase 1a monotherapy [ Time Frame: 21 days ]
    the half life of ELVN-002 calculated from the concentration of ELVN-002 in blood

  8. PK parameter of area under the curve of ELVN-002 in Phase 1b monotherapy [ Time Frame: 21 days ]
    the concentration of ELVN-002 measured in the blood over 24 hours at steady state

  9. PK parameter of maximum concentration of ELVN-002 in Phase 1b monotherapy [ Time Frame: 21 days ]
    the maximum concentration of ELVN-002 measured in the blood at any time point at steady state

  10. PK parameter of terminal half life of ELVN-002 in Phase 1b monotherapy [ Time Frame: 21 days ]
    the half life of ELVN-002 calculated from the concentration of ELVN-002 in blood



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Phase 1a Monotherapy Dose Escalation and Exploration:

  • Pathologically documented advanced stage solid tumor
  • Progressed following all standard treatment or not appropriate for standard treatment
  • HER2 mutation, HER2 amplification or HER2 positive based on local testing

Phase 1b Monotherapy

  • Pathologically documented unresectable and/or metastatic non-squamous NSCLC
  • HER2 mutation identified by tissue (fresh or archival) or ctDNA. Local testing for up to 20 patients the remainder centrally confirmed.
  • Measurable disease
  • No known epidermal growth factor receptor (EGFR), ROS1, anaplastic lymphoma kinase (ALK), or BRAF V600E mutation
  • Progressed after receiving at least 1 prior systemic therapy including a platinum-based chemotherapy with or without immunotherapy, or not appropriate for standard treatment.
  • No prior HER2 tyrosine kinase inhibitor. Prior HER2 directed antibodies or anti-body drug conjugates are allowed
  • No limit on prior number of therapies

Phase 1a Combination with T-DXd

  • Pathologically documented advanced stage NSCLC
  • Progressed after receiving at least 1 prior systemic therapy.
  • HER2 mutation based on local/historical testing of tissue or circulating tumor DNA
  • No known EGFR, ROS1, ALK, or BRAF V600E mutation
  • No prior T-DXd
  • No clinically severe pulmonary compromise
  • No limit on prior number of therapies

Phase 1a Combination Breast Cancer

  • Documented HER2 positive (Immunohistochemical [IHC] 3+ or IHC2+/in situ hybridization (ISH+) breast cancer
  • Must have previously received trastuzumab, a taxane, and T-DXd (if available and appropriate) in the metastatic setting.
  • No limit on prior number of therapies
  • No prior T-DM1

All Phases

  • Eastern Cooperative Oncology Group performance status of 0-1
  • Left ventricular ejection fraction ≥ 50%
  • Platelet count ≥ 100 x 109/L
  • Hemoglobin ≥ 8.5 g/dL
  • Absolute neutrophil count ≥1.0 x 109/L
  • Total bilirubin < 1.5 times upper limit of normal range (ULN), except for patients with Gilbert's syndrome
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 3 times ULN. In the setting of liver metastases < 5 times ULN.
  • Creatinine clearance ≥ 60 mL/minute

Exclusion Criteria All Phases:

  • Severe cardiac arrhythmias, requiring treatment, symptomatic congestive heart failure, myocardial infarction within 28 days prior to first dose, or unstable angina.
  • Another active malignancy within 2 years except basal cell skin cancer and carcinoma in situ treated curatively
  • Active or chronic liver disease
  • Active infection requiring systemic therapy within 14 days before the first dose
  • Brain lesion requiring immediate local therapy
  • Leptomeningeal disease
  • Uncontrolled seizures
  • Corrected QT interval (QTc) of >470 milliseconds (ms) females or >450 ms for males by Fridericia (QTcF)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05650879


Contacts
Layout table for location contacts
Contact: Helen L Collins, MD 707 799-3272 helen.collins@enliventherapeutics.com
Contact: Sabine Tricon sabine.tricon@enliventherapeutics.com

Locations
Show Show 38 study locations
Sponsors and Collaborators
Enliven Therapeutics
Layout table for additonal information
Responsible Party: Enliven Therapeutics
ClinicalTrials.gov Identifier: NCT05650879    
Other Study ID Numbers: ELVN-002-001
First Posted: December 14, 2022    Key Record Dates
Last Update Posted: May 23, 2024
Last Verified: May 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Enliven Therapeutics:
HER2 genetic alterations
HER2 mutation
ELVN-002
Non-small cell lung cancer
HER-2 positive metastatic breast cancer
Enhertu
trastuzumab emtansine
fam-trastuzumab deruxtecan-nxki
Kadcyla
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Neoplasms by Site
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Trastuzumab
Ado-Trastuzumab Emtansine
Maytansine
Trastuzumab deruxtecan
Antineoplastic Agents, Immunological
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunotoxins
Immunoconjugates
Immunologic Factors
Physiological Effects of Drugs